Abstract:Food allergies are common and affect 6-8% of children in the United States; they pose a significant burden on the quality of life of children with allergy and their caregivers due to multiple daily restrictions. Despite the recommended dietary avoidance, reactions tend to occur due to unintentional exposure to the allergenic food trigger. Fear of accidental ingestions with potentially severe reactions, including anaphylaxis and death, creates anxiety in individuals with food allergy. Oral immunotherapy has emerged as a form of active and potentially disease-modifying treatment for common food allergies encountered in childhood. The efficacy of oral immunotherapy is high, with the majority of participants achieving desensitization and, as a result, protection from trace exposures and improved quality of life. The main risk of oral immunotherapy consists of allergic reactions to treatment. In general, rates of allergic reactions and anaphylaxis are reported to be higher in individuals pursuing therapy options, but most subjects who undergo oral immunotherapy will likely experience mild or moderate reactions during treatment. Adverse events tend to reduce in both frequency and number in the maintenance period. The use of immune modulators alongside oral immunotherapy has been suggested, with the aim to improve efficacy and safety, and to facilitate the overall process. It is evident that the landscape of food allergy management is changing and that the future looks brighter, with different options emerging over time. The process of how to choose the appropriate option becomes a discussion between the clinician and the patient, which involves a joint review of the current medical evidence but also the patient's preference for balancing particular attributes of the treatment. By working together, providers and patients will ensure achievement of the best possible outcome for children with food allergies.

News beyond our pages - June 2024

The hype and hope of new food allergy treatments

Omalizumab Implementation in Practice: Lessons Learned from the OUtMATCH Study

Combination of Omalizumab with Allergen Immunotherapy Versus Immunotherapy Alone for Allergic Diseases: A Meta-Analysis of Randomized Controlled Trials

Human vaccines and immunotherapeutics: News February 2024

The OUtMATCH study: treating multiple allergies

The Future of Food Allergy Management: Advancements in Therapies

Diagnosis and management of food allergies: new and emerging options: a systematic review

Biologics in Food Allergies: Emerging Therapies

Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)

A Practical Guide for Implementing Omalizumab Therapy for Food Allergy

Omalizumab (Xolair) for Food Allergy

The Role of Biologics in the Treatment of Food Allergy

Omalizumab for the reduction of allergic reactions to foods: a narrative review

Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab

The Immunobiology and Treatment of Food Allergy

Weighing the benefits and risks of oral immunotherapy in clinical practice

'Breakthrough' allergy drug: injection protects against severe food reactions

Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study

Current perspective on allergen immunotherapy for food allergies

New developments in allergen immunotherapy